<DOC>
	<DOCNO>NCT02107430</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/PCa add radical primary prostatectomy improve PSA progression time within 5 year patient high risk localize Prostate Cancer .</brief_summary>
	<brief_title>Phase II Study DCVAC/PCa After Primary Radiotherapy Patients With High Risk Localized Prostate Cancer</brief_title>
	<detailed_description>Treatment post radical primary prostatectomy Treatment post standard radiotherapy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 year old Histologically confirm localized prostate cancer high risk high risk fulfil least one following : T3T4 stage Gleason Score 810 PSA level 20 ng/ml Indication prostate cancer radical radiotherapy Neoadjuvant androgen androgendeprivation therapy due prostate cancer use Luteinizinghormonereleasing hormone ( LHRH ) analogues ongoing least two month longer 12 month prior randomization Eastern Cooperative Oncology Group ( ECOG ) 02 Primary surgical treatment prostate cancer Prior ongoing chemotherapy prostate cancer Participation clinical study administration evaluate drug within 30 day prior screen Unresolved lasting obstruction urinary system Other uncontrolled intercurrent illness Treatment immunotherapy Prostate Cancer Clinically significant cardiovascular disease History primary immunodeficiency Active autoimmune disease require treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological , Vaccine</keyword>
</DOC>